Table 3. GSEA analysis for the effect of IMO-8400 over canonical pathways (C2 collection) and psoriasis related pathways (a selection of the significant pathways is presented).

MolSigDb C2 collection	N	ES	NES	FDR
IL-23 Pathway (PID)	31	-0.84	-2.57	<10-4
Cytokine Receptor Interaction (KEGG)	191	-0.61	-2.54	<10-4
Cell Cycle (Reactome)	344	-0.55	-2.46	<10-4
IL-12 Pathway (PID)	56	-0.68	-2.35	<10-4
Graft Versus Host Disease (KEGG)	23	-0.80	-2.24	4.94E-05
IL-27 Pathway (PID)	23	-0.77	-2.23	4.09E-05
Type I Diabetes Mellitus (KEGG)	24	-0.75	-2.17	1.01E-04
Natural Killer Cell Mediated Cytotoxicity (KEGG)	93	-0.58	-2.15	3.23E-04
Allograft Rejection (KEGG)	22	-0.76	-2.12	5.30E-04
Chemokine Signaling Pathway (KEGG)	161	-0.50	-2.04	0.0017
JAK-STAT Signaling Pathway (KEGG)	113	-0.52	-2.02	0.0019
Interferon Signaling (Reactome)	117	-0.51	-2.00	0.0023
Toll Endogenous Pathway (PID)	23	-0.70	-1.99	0.0029
Toll-Like Receptor Signaling Pathway (KEGG)	81	-0.53	-1.96	0.0046
STAT3 Pathway (ST)	11	-0.81	-1.90	0.0076
IL-6 Pathway (PID)	44	-0.53	-1.76	0.0293
Psoriasis-related gene sets
Genes down-regulated after 2 weeks of IL-17 antagonist Ixekinumab	675	-0.57	-2.70	<10-4
Up-regulated by IFNγin Normal Skin (JID, 2012)	722	-0.53	-2.54	<10-4
KC IL-17 Up	41	-0.72	-2.36	<10-4
RHE IFNγ Up	178	-0.56	-2.33	<10-4
Fibroblasts IL-17 Up	37	-0.73	-2.29	<10-4
Additive IL-17 & IL-22 KC	19	-0.74	-2.02	3.51x10-4
Synergistic IL-17 & IL-22 KC	26	-0.67	-2.00	4.05 x10-4
KC IFNα Up	24	-0.69	-1.98	6.19 x10-4
Additive IL-17 & TNFα in KC	165	-0.43	-1.76	0.0062
Synergistic IL-17 & TNFα in KC	128	-0.38	-1.51	0.0386
KC TNF Up	460	-0.31	-1.42	0.0633
KC IFNγUp	872	-0.28	-1.33	0.0957

N = number of genes detected in each pathway